Peroxisome proliferator-activated receptors in inflammation control

被引:624
|
作者
Delerive, P
Fruchart, JC
Staels, B [1 ]
机构
[1] Univ Lille 2, Fac Pharm, F-59000 Lille, France
[2] Inst Pasteur, Dept Atherosclerose, INSERM, U325, F-59019 Lille, France
关键词
D O I
10.1677/joe.0.1690453
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors belonging to the nuclear receptor superfamily. PPAR alpha is highly expressed in liver, skeletal muscle, kidney, heart and the vascular wall. PPAR gamma is predominantly detected in adipose tissue, intestine and macrophages. PPARs are activated by fatty-acid derivatives and pharmacological agents such as fibrates and glitazones which are specific for PPAR alpha and PPAR gamma respectively. PPARs regulate lipid and lipoprotein metabolism, glucose homeostasis, cell proliferation and differentiation, and apoptosis. PPAR alpha controls intra- and extracellular lipid metabolisms whereas PPAR gamma triggers adipocyte differentiation and promotes lipid storage. In addition, PPARs also modulate the inflammatory response. PPAR activators have been shown to exert anti-inflammatory activities in various cell types by inhibiting the expression of proinflammatory genes such as cytokines, metalloproteases and acute-phase proteins. PPARs negatively regulate the transcription of inflammatory response genes by antagonizing the AP-1, nuclear factor-kappaB (NF-kappaB), signal transducer and activator of transcription and nuclear factor of activated T-cells signalling pathways and by stimulating the catabolism of proinflammatory eicosanoids. These recent findings indicate a modulatory role PPARs in inflammation with potential therapeutical applications in chronic inflammatory diseases.
引用
收藏
页码:453 / 459
页数:7
相关论文
共 50 条
  • [21] Peroxisome proliferator-activated receptors: good and bad
    Staels, B.
    CHEMISTRY AND PHYSICS OF LIPIDS, 2008, 154 : S15 - S16
  • [22] Peroxisome proliferator-activated receptors and skin development
    Rosenfield, RL
    Deplewski, D
    Greene, ME
    HORMONE RESEARCH, 2000, 54 (5-6) : 269 - 274
  • [23] Peroxisome proliferator-activated receptors and the cardiovascular system
    Chen, YQE
    Fu, MG
    Zhang, JF
    Zhu, XJ
    Lin, YM
    Akinbami, MA
    Song, Q
    VITAMINS AND HORMONES - ADVANCES IN RESEARCH AND APPLICATIONS, VOL 66, 2003, 66 : 157 - 188
  • [24] Role of peroxisome proliferator-activated receptors in osteoarthritis
    Huang, Gang
    Jiang, Wei
    Xie, Weiyong
    Lu, Wei
    Zhu, Weimin
    Deng, Zhenhan
    MOLECULAR MEDICINE REPORTS, 2021, 23 (02)
  • [25] Nuclear Peroxisome Proliferator-Activated Receptors and Thiazolidinediones
    Grinberg, Achikam
    Park, Kyung W.
    INTERNATIONAL ANESTHESIOLOGY CLINICS, 2005, 43 (02) : 1 - 21
  • [26] Peroxisome proliferator-activated receptors and insulin secretion
    Terauchi, Y
    Kadowaki, T
    ENDOCRINOLOGY, 2005, 146 (08) : 3263 - 3265
  • [27] The role of peroxisome proliferator-activated receptors in endometriosis
    Psilopatis, Iason
    Theocharis, Stamatios
    Beckmann, Matthias W.
    FRONTIERS IN MEDICINE, 2024, 11
  • [28] Modulators of peroxisome proliferator-activated receptors (PPARs)
    Sternbach, DD
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 38, 2003, 38 : 71 - 80
  • [29] Fibrates, Glitazones, and Peroxisome Proliferator-Activated Receptors
    Lalloyer, Fanny
    Staels, Bart
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2010, 30 (05) : 894 - 899
  • [30] Lipid metabolism: peroxisome proliferator-activated receptors
    van Heyningen, Charles
    CURRENT OPINION IN LIPIDOLOGY, 2007, 18 (04) : 470 - 472